Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
344 - Hi Patrick, Lately PAAB has been requesting that the indication for a product be placed on the front page of every piece. If we are not making any clinical claims on a front page of a piece, why can we not include the indication on the second page of a piece? Your PAAB code clearly says: 2.10.2 - PAAB code, The TMA content, "Drug X is indicated for" (or equivalent) must be presented verbatim at least once within the advertising message of the APS. Nowhere does it say it has to be on the front page.....thanks!
-
Section 2.10.1 states that this information "must be presented prominently among or prior to the first set of marketing benefit claims". Per the definition section of the PAAB code, such claims can be therapeutic or non therapeutic. The front page often (although not always) contains a claim of marketing benefit. The underlying principle is that the segment of patients for whom the product is authorized should set the context for the corresponding benefits. Also refer to the guidance document "Guidance on Indication Placement in Advertising" on the PAAB website.
